Business
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.","length":494,"tagName":"p"},{"type":"text","content":"A replay of the event can be found on the Investors section of the Company's website at https://investors.aytubio.com under Events & Presentations. The event can also be accessed directly at https://app.webinar.net/Qo7DrDvVzq8.","length":235,"tagName":"p"},{"type":"text","content":"The Investor Day primarily focused on EXXUA™ (gepirone), extended-release tablets ("EXXUA"), the first and only 5HT1a agonist approved by the United States Food and Drug Administration ("FDA") for the treatment of major depressive disorder ("MDD"), which was initially launched last month.","length":319,"tagName":"p"},{"type":"text","content":"Key Opinion Leaders ("KOLs") in the field of psychiatry and Aytu's senior management team presented on the EXXUA opportunity and led question and answer sessions.","length":176,"tagName":"p"},{"type":"text","content":"KOL Presentation Highlights","length":27,"tagName":"p"},{"type":"text","content":"Stephen M. Stahl, MD, PhD, DSc (Hon) reviewed the 5-HT1a receptor and its clinical importance in MDD.","length":101,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"padding:.25pt;vertical-align:top;width:.25in;","val":[]},{"style":"padding:.25pt;vertical-align:top;width:.25in;","val":[{"type":"text","content":"●","length":1,"tagName":"p"}]},{"style":"padding:.25pt;vertical-align:top;","val":[{"type":"text","content":"Selective Serotonin Reuptake Inhibitors ("SSRIs") and Serotonin-Norepinephrine Reuptake Inhibitors ("SNRIs"), collectively Reuptake Inhibitors, 'flood the synapse' with serotonin, non-selectively binding multiple 5-HT receptor types.","length":261,"tagName":"p"}]}]}],"length":262},{"type":"table","headerItems":[],"items":[{"val":[{"style":"padding:.25pt;vertical-...